Board agrees to review patent covering certain strengths of blockbuster diabetes drug
The U.S. Patent and Trademark Office’s patent trial and appeal board has agreed to review a Novo Nordisk NVO, +1.44% patent covering certain strengths of Ozempic, a Viatris VTRS, +0.52% spokesperson said Wednesday. The patent challenge was filed by Mylan Pharmaceuticals, which is now part of Viatris.
In the decision dated Wednesday, the patent trial and appeal board said that based on the arguments and evidence presented thus far, the board is persuaded that Mylan “has demonstrated a reasonable likelihood that it would prevail with respect to at least one claim challenged in the petition.”
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Ozempic Patient Reveals 'Excruciating' New Side EffectAn Ozempic patient reported that she was in 'excruciating pain' due to the side effects she experienced, including burning rashes.
続きを読む »
Snack Food CEO Vows to Battle OzempicThis snack food overlord is readying himself and his company's delicious treats for war against weight loss drugs like Ozempic.
続きを読む »
Ozempic burned off my genitals — I found pieces of charred skin on the toilet“My genitals, anus, and buttocks were severely burned, some areas with charred skin. It was as if I was exposed to sunlight for days.”
続きを読む »
Here’s Why The FDA Added a New Warning to Ozempic’s LabelSince 2018, Ozempic has been linked to nearly 9,000 cases of gastrointestinal side effects, including vomiting, nausea, and abdominal pain.
続きを読む »
America’s Food Giants Confront the Ozempic EraOzempic and other weight-loss drugs can list at $900 or more per month. WSJ’s Anna Wilde Mathews joins host J.R. Whalen to discuss how to get your health insurance plan to cover these prescriptions.
続きを読む »